A large population-based prospective cohort study (Prostate Cancer data Base Sweden, PCBaSe) on prostate cancer in T2D patients reported a decreased cancer risk only for insulin and sulfonylurea users but not for MTF users (HR 0.96, 95% CI 0.77–1.19) [144]. The gene discussed is INS; the disease is prostate carcinoma.